首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up
【2h】

Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up

机译:Verteporfin的光动力疗法治疗中国眼病理性近视的小凹下脉络膜新生血管:随访期为1年和2年

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Aims: To evaluate the visual and fluorescein angiographic outcomes of photodynamic therapy (PDT) with verteporfin in patients with subfoveal choroidal neovascularisation (CNV) caused by pathologic myopia in the Chinese.>Methods: Prospective, non-comparative, two centre interventional study. Patients with CNV secondary to pathologic myopia of Chinese ethnicity were recruited and treated with a standard regimen of PDT with verteporfin. Results of this study in Chinese eyes with pigmented retinal pigment epithelium were compared with those from the Verteporfin in Photodynamic Therapy (VIP) Study of predominantly white eyes.>Results: Thirty one and 22 eyes that completed the 12 month and 24 month follow up studies respectively were analysed. The mean and median best corrected visual acuities (BCVA) could be maintained at the baseline level at the 12 month and 24 month visits. Fourteen (63.6%) eyes had stable or improved BCVA at 24 months and six (27.3%) of them had a moderate gain in vision (improved by three or more lines). Visual results were comparable with that of the VIP study, but the average accumulative PDT treatments required in one and two years were 1.7 and 2.3 respectively, which were significantly less than 3.4 and 5.1 treatments in VIP study. Mean logMAR BCVA of the younger age group (<55 years) at 24 months was 0.41 (SD 0.29), which was significantly better than the older age group (⩾ = 55 years) of 0.82 (SD 0.40) (Mann-Whitney U test, p = 0.029).>Conclusions: PDT using the predetermined treatment protocol has achieved similar visual outcomes in the Chinese population as in white people with subfoveal myopic CNV over a 2 year study period. The complete cessation of CNV leakage can be accomplished, on average, with fewer PDT retreatments than reported in the VIP study. The disparity may be due to ethnic differences in these two populations.
机译:>目的:在中国因病理性近视引起的小凹下脉络膜新生血管形成(CNV)患者中,评价采用Verteporfin进行光动力疗法(PDT)的视觉和荧光血管造影结果。>方法:前瞻性,非对照,两中心干预研究。招募了华裔病理性近视继发的CNV患者,并采用标准的PDT联合维替泊芬治疗。将该研究结果与视网膜色素上皮色素沉着的中国人眼睛与Verteporfin的光动力疗法(VIP)中主要为白眼的人进行了比较。>结果:十二个月中有31只眼和22只眼对24个月的随访研究进行了分析。在第12个月和第24个月就诊时,最佳矫正视力(BCVA)的平均值和中位数可以保持在基线水平。在24个月时,有十四只(63.6%)眼睛的BCVA稳定或好转,其中六只(27.3%)的视力得到了中等程度的改善(三行或更多行得到改善)。视觉结果与VIP研究相当,但一年和两年所需的平均PDT累积治疗分别为1.7和2.3,大大低于VIP研究中的3.4和5.1治疗。年龄较小组(<55岁)在24个月时的平均logMAR BCVA为0.41(标准差0.29),明显好于年龄较大组(group = 55岁)的0.82(标准差0.40)(Mann-Whitney U检验) ,p = 0.029)。>结论:在为期2年的研究期间,采用预定治疗方案的PDT在中国人群中的视觉效果与在小凹近视CNV的白人中相似。平均而言,与VIP研究报告相比,用更少的PDT再处理可以完全停止CNV泄漏。差异可能是由于这两个人口的种族差异造成的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号